Zhitong Finance App News, Danno Pharmaceutical-B (06872.HK) issued an announcement. After comprehensive consideration of existing clinical data, unmet clinical needs, competitive landscape and commercial potential of the new drug candidate rifuquinone (TNP-2092), the company has selected the treatment of artificial joint infections (PJI) through intra-articular injection as the core priority development indication for rifuquinone.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.